EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The evaluation of hepatitis B positivity in fully vaccinated children with juvenile idiopathic arthritis

Sümeyra Özdemir Çiçek, Nihal Şahin, Ayşenur Paç Kısaarslan, Meda Kondolot, Ruhan Düşünsel, Muammer Hakan Poyrazoğlu

Trends in Pediatrics · 29.03.2026 · 7 (1) · 43-51

DOI: 10.59213/tp.2026.285 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Trends in Pediatrics, online erschienen am 29.03.2026. Verfasst von Sümeyra Özdemir Çiçek und 5 weiteren Autor:innen. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Biologic disease-modifying antirheumatic drugs (bDMARDs) have been frequently used to treat juvenile idiopathic arthritis (JIA) resistant to classical (c) DMARDs. There is concern that vaccines may reduce vaccine effectiveness due to their immunosuppressive effects. This study aimed to evaluate the prevalence of anti-hepatitis B surface (HBs) antibody positivity in JIA patients treated with bDMARDs and to compare it with that in JIA patients treated with cDMARDs and in healthy controls. Materials and Methods: Anti-HBs antibody positivity and titers were compared between patients with JIA treated with bDMARDs or only cDMARDs, followed in our clinic, and healthy controls aged 2-20 years. All participants were vaccinated in infancy according to the routine vaccination schedule in our country. Anti-HBs titers ≥10 IU/L were considered seroprotective.

Results

Ninety-two JIA patients receiving cDMARDs, 92 receiving bDMARDs, and 91 healthy controls were included in the study. The median time from the last vaccination to the study was 12.5 (min-max:3.5-17.55) years in controls, 12.5 (min-max:1.75-19.5) years in patients with cDMARDs, and 13.0 (min-max:2.25-19.0) years in patients with bDMARDs (p=0.060). Anti-HBs was positive in 50 (54.9%) controls, 66 (71.7%) patients with cDMARDs, and 62 (67.4%) patients with bDMARDs (p=0.048). Age, time from vaccination to study, and duration of bDMARD use were found to be risk factors for anti-HBs negativity in univariate regression analyses. According to the multivariable analysis of these three variables, the duration of bDMARD use was an independent risk factor for anti-HBs negativity (OR: 1.023, 95% CI: 1.005-1.041, p=0.013). Anti-HBs negativity was associated with a duration of bDMARDs longer than 32 months (AUC: 0.658, 95%CI: 0.541-0.776, p=0.014) with 60.0% sensitivity, and 59.7% specificity.

Conclusions

A longer duration of bDMARDs was found to be a risk factor for anti-HBs negativity. Physicians should be careful in terms of anti-HBs negativity when the duration of biologics use is prolonged.

Zitieren

APA

Çiçek, S. Ö., Şahin, N., Kısaarslan, A. P., Kondolot, M., Düşünsel, R., & Poyrazoğlu, M. H. (2026). The evaluation of hepatitis B positivity in fully vaccinated children with juvenile idiopathic arthritis. Trends in Pediatrics, 7(1), 43-51. https://doi.org/10.59213/tp.2026.285

Vancouver

Çiçek SÖ, Şahin N, Kısaarslan AP, Kondolot M, Düşünsel R, Poyrazoğlu MH. The evaluation of hepatitis B positivity in fully vaccinated children with juvenile idiopathic arthritis. Trends in Pediatrics. 2026;7(1):43-51. doi:10.59213/tp.2026.285

BibTeX
@article{iek2026,
  author = {Çiçek, Sümeyra Özdemir and Şahin, Nihal and Kısaarslan, Ayşenur Paç and Kondolot, Meda and Düşünsel, Ruhan and Poyrazoğlu, Muammer Hakan},
  title = {The evaluation of hepatitis B positivity in fully vaccinated children with juvenile idiopathic arthritis},
  journal = {Trends in Pediatrics},
  year = {2026},
  volume = {7},
  number = {1},
  pages = {43--51},
  doi = {10.59213/tp.2026.285}
}
Kostenlos starten →